


Figure S5: Mean probability of experiencing an irAE (upper panels) or IRR (lower panels) for weight-based (10 mg/kg Q2W) and flat (800 mg Q2W) dosing with avelumab based on the steady-state population pharmacokinetic model.



Box and whisker plots for (a) probability of irAEs based on $C_{trough,ss}$ in all patients; (b) probability of irAEs based on $C_{trough,ss}$ stratified by quartiles of weight; (c) box and whisker plots for probability of IRRs based on $C_{max,ss}$ in all patients; and (d) probability of IRRs based on $C_{max,ss}$ stratified by quartiles of weight. $C_{max,ss}$, steady-state maximum concentration; $C_{trough,ss}$, steady-state trough concentration; irAE, immune-related adverse event; IRR, infusion-related reaction; Q2W, every 2 weeks.